{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:09:38Z","timestamp":1782886178291,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021MH363"],"award-info":[{"award-number":["ZR2021MH363"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81600601"],"award-info":[{"award-number":["81600601"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Orthop Surg Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>This study investigates the efficacy of multidisciplinary fusion therapy based on 3D reconstruction technology for the treatment of gouty stone by comparing the efficacy of multidisciplinary fusion therapy with pharmacologic therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study is a cohort study.Patients who underwent gout stone surgery at the Affiliated Hospital of Qingdao University from November 2020 to November 2022 were included in this study, totaling 85 to form the MDT surgery group, and matched among gout stone patients in the outpatient clinic during the same period to form the medication group. Patients in the 2 groups were followed up for 6 months to compare baseline and follow-up data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Both groups experienced a decrease in uric acid levels and an increase in SF-36 scores during follow-up. After adjusting for confounders, multifactorial logistic regression showed that the uric acid attainment rate of patients in the MDT surgery group was 4.011 times higher than that of the drug group (OR: 4.011, 95% CI: 1.595, 10.086, <jats:italic>P<\/jats:italic>\u2009=\u20090.003); the proportion of patients with an increase in SF-36 in the MDT surgery group was 4.976 times higher than that of the drug group (OR: 4.976, 95% CI: 2.243, 11.040, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001); the proportion of patients treated with high-dose medication in the MDT surgery group was 1.8% of that of patients in the drug group (OR: 0.018, 95% CI: 0.002, 0.148, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001); and the proportion of patients in the MDT surgery group who developed frequent gout was 2.8% of that in the drug group (OR: 0.028 95% CI: 0.003, 0.2398, <jats:italic>P<\/jats:italic>\u2009=\u20090.001). the proportion of patients in the MDT surgery group who developed abnormal liver function was 0.317 times higher than that in the drug group (OR: 0.317, 95% CI: 0.121, 0.831, <jats:italic>P<\/jats:italic>\u2009=\u20090.019).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The multidisciplinary integration of 3D reconstructive techniques for gout stone treatment resulted in an increase in uric acid compliance, a decrease in the frequency of gout and the appearance of liver impairment; and a greater benefit in terms of improvement in the quality of life of the patients after treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13018-025-05506-8","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T04:23:12Z","timestamp":1738642992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Analysis of the efficacy of multidisciplinary integration based on 3D reconstruction technology for the treatment of gout stone"],"prefix":"10.1186","volume":"20","author":[{"given":"Shizhe","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengxiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehai","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"5506_CR1","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","volume":"16","author":"M Dehlin","year":"2020","unstructured":"Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16:380\u201390.","journal-title":"Nat Rev Rheumatol"},{"key":"5506_CR2","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/1756-185X.13266","volume":"21","author":"KH Yu","year":"2018","unstructured":"Yu KH, Chen DY, Chen JH, Chen SY, Chen SM, Cheng TT, Hsieh SC, Hsieh TY, Hsu PF, Kuo CF, Kuo MC, Lam HC, Lee IT, Liang TH, Lin HY, Lin SC, Tsai WP, Tsay GJ, Wei JC, Yang CH, Tsai WC. Management of gout and hyperuricemia: multidisciplinary consensus in Taiwan. Int J Rheum Dis. 2018;21:772\u201387.","journal-title":"Int J Rheum Dis"},{"key":"5506_CR3","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1080\/00325481.2016.1221732","volume":"128","author":"G Ruoff","year":"2016","unstructured":"Ruoff G. N.L. Edwards 2016 Overview of serum uric acid treatment targets in gout: why Less Than 6\u00a0mg\/dL? Postgrad Med 128 706\u201315.","journal-title":"Postgrad Med"},{"key":"5506_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/rheumatology\/kew383","volume":"56","author":"M Sapsford","year":"2017","unstructured":"Sapsford M, Gamble GD, Aati O, Knight J, Horne A, Doyle AJ, Dalbeth N. Relationship of bone erosion with the urate and soft tissue components of the gout stone in gout: a dual energy computed tomography study. Rheumatology (Oxford). 2017;56:129\u201333.","journal-title":"Rheumatology (Oxford)"},{"key":"5506_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semarthrit.2017.12.005","volume":"48","author":"P Chandratre","year":"2018","unstructured":"Chandratre P, Mallen C, Richardson J, Muller S, Hider S, Rome K, Blagojevic-Bucknall M, Roddy E. Health-related quality of life in gout in primary care: baseline findings from a cohort study. Semin Arthritis Rheum. 2018;48:61\u20139.","journal-title":"Semin Arthritis Rheum"},{"key":"5506_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13047-017-0207-4","volume":"10","author":"S Stewart","year":"2017","unstructured":"Stewart S, Dalbeth N, Otter S, Gow P, Kumar S, Rome K. Clinically-evident tophi are associated with reduced muscle force in the foot and ankle in people with gout: a cross-sectional study. J Foot Ankle Res. 2017;10:25.","journal-title":"J Foot Ankle Res"},{"key":"5506_CR7","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1053\/j.jfas.2018.06.002","volume":"57","author":"X Zhao","year":"2018","unstructured":"Zhao X, Tsujimoto T, Kim B, Katayama Y, Tanaka K. Association of Foot structure with the strength of muscles that move the ankle and physical performance. J foot Ankle Surgery: Official Publication Am Coll Foot Ankle Surg. 2018;57:1143\u20137.","journal-title":"J foot Ankle Surgery: Official Publication Am Coll Foot Ankle Surg"},{"key":"5506_CR8","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1093\/rheumatology\/kem246","volume":"46","author":"N Dalbeth","year":"2007","unstructured":"Dalbeth N, Collis J, Gregory K, Clark B, Robinson E, McQueen FM. Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology (Oxford). 2007;46:1804\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"5506_CR9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3899\/jrheum.160596","volume":"44","author":"ZL Vincent","year":"2017","unstructured":"Vincent ZL, Gamble G, House M, Knight J, Horne A, Taylor WJ, Dalbeth N. Predictors of mortality in people with recent-onset gout: a prospective observational study. J Rhuematol. 2017;44:368\u201373.","journal-title":"J Rhuematol"},{"key":"5506_CR10","doi-asserted-by":"publisher","first-page":"e009328","DOI":"10.1161\/JAHA.118.009328","volume":"7","author":"NJ Pagidipati","year":"2018","unstructured":"Pagidipati NJ, Clare RM, Keenan RT, Chiswell K, Roe MT, Hess CN. Association of gout with Long-Term Cardiovascular outcomes among patients with obstructive coronary artery disease. J Am Heart Association. 2018;7:e009328.","journal-title":"J Am Heart Association"},{"key":"5506_CR11","doi-asserted-by":"crossref","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liot\u00e9 F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64:1431\u201346.","DOI":"10.1002\/acr.21772"},{"key":"5506_CR12","first-page":"1888","volume":"34","author":"F Perez-Ruiz","year":"2007","unstructured":"Perez-Ruiz F, Martin I, Canteli B. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rhuematol. 2007;34:1888\u201393.","journal-title":"J Rhuematol"},{"key":"5506_CR13","first-page":"746","volume":"35","author":"D Peiteado","year":"2017","unstructured":"Peiteado D, Villalba A, Mart\u00edn-Mola E, Balsa A, De Miguel E. Ultrasound sensitivity to changes in gout: a longitudinal study after two years of treatment. Clin Exp Rheumatol. 2017;35:746\u201351.","journal-title":"Clin Exp Rheumatol"},{"key":"5506_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40001-022-00982-8","volume":"28","author":"DH Yang","year":"2023","unstructured":"Yang DH, Chen HC, Wei JC. Early urate-lowering therapy in gouty arthritis with acute flares: a double-blind placebo controlled clinical trial. Eur J Med Res. 2023;28:10.","journal-title":"Eur J Med Res"},{"key":"5506_CR15","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1007\/s10067-020-05079-3","volume":"39","author":"AM Hu","year":"2020","unstructured":"Hu AM, Brown JN. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review. Clin Rheumatol. 2020;39:3287\u201394.","journal-title":"Clin Rheumatol"},{"key":"5506_CR16","doi-asserted-by":"publisher","first-page":"811323","DOI":"10.3389\/fimmu.2021.811323","volume":"12","author":"S Li","year":"2021","unstructured":"Li S, Xu G, Liang J, Wan L, Cao H, Lin J. The role of Advanced imaging in gout management. Front Immunol. 2021;12:811323.","journal-title":"Front Immunol"},{"key":"5506_CR17","first-page":"197","volume":"40","author":"C Schwabl","year":"2021","unstructured":"Schwabl C, Taljanovic M, Widmann G, Teh J, Klauser AS. Ultrasonography and dual-energy computed tomography: impact for the detection of gouty deposits. Ultrasonography (Seoul Korea). 2021;40:197\u2013206.","journal-title":"Ultrasonography (Seoul Korea)"},{"key":"5506_CR18","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","volume":"74","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJ, Liot\u00e9 F, Naden RP, Nuki G, Ogdie A, Perez-Ruiz F, Saag K, Singh JA, Sundy JS, Tausche AK, Vaquez-Mellado J, Yarows SA, Taylor WJ. 2015 gout classification criteria: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74:1789\u201398.","journal-title":"Ann Rheum Dis"},{"key":"5506_CR19","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.bjps.2013.03.041","volume":"66","author":"SS Lee","year":"2013","unstructured":"Lee SS, Chen MC, Chou YH, Lin SD, Lai CS, Chen YC. Timing of intra-lesion shaving for surgical treatment of chronic gout stone. J Plast Reconstr Aesthetic Surgery: JPRAS. 2013;66:1131\u20137.","journal-title":"J Plast Reconstr Aesthetic Surgery: JPRAS"},{"key":"5506_CR20","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.semarthrit.2020.04.008","volume":"50","author":"JA Singh","year":"2020","unstructured":"Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum. 2020;50:S11\u20136.","journal-title":"Semin Arthritis Rheum"},{"key":"5506_CR21","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40744-019-00173-8","volume":"6","author":"F Zhang","year":"2019","unstructured":"Zhang F, Liu Z, Jiang L, Zhang H, Zhao D, Li Y, Zou H, Wang X, Li X, Shi B, Xu J, Yang H, Hu S, Qu S, Randomized A. Double-Blind, Non-inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese subjects with or without gout. Rheumatol Therapy. 2019;6:543\u201357.","journal-title":"Rheumatol Therapy"},{"key":"5506_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10157-020-01851-6","volume":"24","author":"T Hosoya","year":"2020","unstructured":"Hosoya T, Furuno K, Kanda S. A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout. Clin Exp Nephrol. 2020;24:71\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"5506_CR23","doi-asserted-by":"crossref","unstructured":"Jordan A, Gresser U. Side effects and interactions of the Xanthine oxidase inhibitor febuxostat. Pharmaceuticals (Basel Switzerland). 2018;11(2):51.","DOI":"10.3390\/ph11020051"},{"key":"5506_CR24","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/art.10511","volume":"47","author":"F Perez-Ruiz","year":"2002","unstructured":"Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47:356\u201360.","journal-title":"Arthritis Rheum"},{"key":"5506_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1477-7525-10-117","volume":"10","author":"PP Khanna","year":"2012","unstructured":"Khanna PP, Nuki G, Bardin T, Tausche AK, Forsythe A, Goren A, Vietri J, Khanna D. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from a cross-sectional survey. Health Qual Life Outcomes. 2012;10:117.","journal-title":"Health Qual Life Outcomes"},{"key":"5506_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12955-023-02111-3","volume":"21","author":"O Alzahrani","year":"2023","unstructured":"Alzahrani O, Fletcher JP, Hitos K. Quality of life and mental health measurements among patients with type 2 diabetes mellitus: a systematic review. Health Qual Life Outcomes. 2023;21:27.","journal-title":"Health Qual Life Outcomes"},{"key":"5506_CR27","doi-asserted-by":"crossref","unstructured":"Oh YJ, Moon KW. Combined use of Febuxostat and Colchicine does not increase Acute Hepatotoxicity in patients with gout: a retrospective study. J Clin Med. 2020;9(5):1488.","DOI":"10.3390\/jcm9051488"},{"key":"5506_CR28","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/14656566.2021.1918102","volume":"22","author":"T Ishikawa","year":"2021","unstructured":"Ishikawa T, Takahashi T, Taniguchi T, Hosoya T. Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout. Expert Opin Pharmacother. 2021;22:1397\u2013406.","journal-title":"Expert Opin Pharmacother"},{"key":"5506_CR29","doi-asserted-by":"publisher","first-page":"372","DOI":"10.5414\/CP203898","volume":"59","author":"T Wakabayashi","year":"2021","unstructured":"Wakabayashi T, Ueno S, Nakatsuji T, Hirai T, Niinomi I, Oyama S, Inada A, Kambara H, Iwanaga K, Hosohata K. Safety profiles of new xanthine oxidase inhibitors: a post-marketing study. Int J Clin Pharmacol Ther. 2021;59:372\u20137.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"5506_CR30","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13075-019-1976-x","volume":"21","author":"N Liang","year":"2019","unstructured":"Liang N, Sun M, Sun R, Xu T, Cui L, Wang C, Ma L, Cheng X, Xue X, Sun W, Yuan X, Zhang H, Li H, He Y, Ji A, Wu X, Li C. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort. Arthritis Res Therapy. 2019;21:200.","journal-title":"Arthritis Res Therapy"},{"key":"5506_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13075-018-1593-0","volume":"20","author":"L Gunawardhana","year":"2018","unstructured":"Gunawardhana L, Becker MA, Whelton A, Hunt B, Castillo M, Saag K. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study. Arthritis Res Therapy. 2018;20:99.","journal-title":"Arthritis Res Therapy"},{"key":"5506_CR32","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3899\/jrheum.180761","volume":"46","author":"JS Lee","year":"2019","unstructured":"Lee JS, Won J, Kwon OC, Lee SS, Oh JS, Kim YG, Lee CK, Yoo B, Hong S. Hepatic Safety of Febuxostat Compared with allopurinol in gout patients with fatty liver disease. J Rhuematol. 2019;46:527\u201331.","journal-title":"J Rhuematol"},{"key":"5506_CR33","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/jcpt.12392","volume":"41","author":"T Hosoya","year":"2016","unstructured":"Hosoya T, Sasaki T, Hashimoto H, Sakamoto R, Ohashi T. Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study. J Clin Pharm Ther. 2016;41:298\u2013305.","journal-title":"J Clin Pharm Ther"},{"key":"5506_CR34","doi-asserted-by":"crossref","unstructured":"Dalbeth N, Saag KG, Palmer WE, Choi HK, Hunt B, MacDonald PA, Thienel U, Gunawardhana L. Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study. Arthritis & rheumatology (Hoboken, N.J.). 2017;69:2386\u20132395.","DOI":"10.1002\/art.40233"},{"key":"5506_CR35","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1681\/ASN.2016050521","volume":"28","author":"DI Jalal","year":"2017","unstructured":"Jalal DI, Decker E, Perrenoud L, Nowak KL, Bispham N, Mehta T, Smits G, You Z, Seals D, Chonchol M, Johnson RJ. Vascular function and uric acid-lowering in Stage 3 CKD. J Am Soc Nephrology: JASN. 2017;28:943\u201352.","journal-title":"J Am Soc Nephrology: JASN"}],"container-title":["Journal of Orthopaedic Surgery and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-025-05506-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13018-025-05506-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-025-05506-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T04:23:18Z","timestamp":1738642998000},"score":1,"resource":{"primary":{"URL":"https:\/\/josr-online.biomedcentral.com\/articles\/10.1186\/s13018-025-05506-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5506"],"URL":"https:\/\/doi.org\/10.1186\/s13018-025-05506-8","relation":{},"ISSN":["1749-799X"],"issn-type":[{"value":"1749-799X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}